Reintroduction of Diazoxide after Diagnosis of Pulmonary Hypertension in a Patient with Transient Hyperinsulinism

Abstract

Our case describes the reintroduction of diazoxide despite life-threatening pulmonary hypertension in our infant due to lack of therapeutic options for congenital hyperinsulinism.

Keywords

congenital hyperinsulinism - diazoxide - pulmonary hypertension - chlorothiazide - side effects

Authors' Contributions

P.N. has made substantial contributions to the conception and design of the work; and helped in drafting the work and substantively revised it and has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

B.S. made substantial contributions to the conception and design of the work; and helped in drafting the work and substantively revised it and has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Publication History

Received: 16 November 2020

Accepted: 10 February 2021

Article published online:
01 April 2021

• References

• 1 Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth 2004; 14 (07) 607-609
• 2 Welters A, Lerch C, Kummer S. et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis 2015; 10 (01) 150
• 3 Demirel F, Unal S, Çetin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2011; 24 (7-8): 603-605
• 4 Herrera A, Vajravelu ME, Givler S. et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab 2018; 103 (12) 4365-4372
• 5 Nebesio TD, Hoover WC, Caldwell RL, Nitu ME, Eugster EA. Development of pulmonary hypertension in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2007; 20 (08) 939-944
• 6 Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017; 38 (06) 1247-1250
• 7 FDA Drug Safety Communication, FDA Warns about a Serious Lung Condition in Infants and Newborns Treated with Proglycem (Diazoxide) [press release]. Food and Drug Administration. Maryland, USA: 2015
• 8 Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J. Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism. Horm Res Paediatr 2019; 91 (01) 25-32
• 9 Gray KD, Dudash K, Escobar C. et al; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018; 38 (11) 1496-1502
• 10 Pediatrics AAo. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127 (03) 575-579
• 11 Silvani P, Camporesi A. Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol 2007; 5 (02) 129-133
• 12 Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther 2008; 25 (05) 515-519